Joined: 12/6/2011
Posts: 3326
|
From Alzheimer's Daily News:
(Source: Reuters) - Danish drugmaker Lundbeck said patients who took its Alzheimer's drug candidate Lu AE58054 in a phase 2 clinical trial achieved statistically significant improvement in cognitive performance when the compound was added to donepezil (brand name Aricept).
Lundbeck said the clinical study involved 278 Alzheimer's patients and achieved its main target and that Lu AE58054 was also well-tolerated in combination with donepezil.
"These results are very encouraging, and we are now evaluating how to best proceed with the development of Lu AE58054," reported Anders Pedersen, head of research and development.
Go to full story: http://www.reuters.com
|